Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DEXCOM INCDXCM · Entity 3114 | EVP, Chief Financal Officer | September 10, 2026 | September 14, 2026 |
| NUVASIVE INCNUVA · Entity 110002 | Chief Accounting Officer | February 01, 2018 | February 05, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DEXCOM INC
Report date September 10, 2026 · Filed September 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 146,828 |
Reported balance
After 2026-09-10 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-10 · Sale · Disposed 3,638 · Balance 146,828 F1: On June 10, 2026, Mr. Sylvain adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sylvain. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2: Included in this number are 87,094 unvested restricted stock units, 48,774 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 23,937 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 5,699 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 8,684 of which were granted on March 8, 2024 and shall vest through March 8, 2027, and 76 additional shares acquired under the Issuer's Amended and Restated 2015 Employee Stock Purchase Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 10, 2026, Mr. Sylvain adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sylvain. The shares set forth above were sold pursuant to the 10b5-1 Plan.
F2: Included in this number are 87,094 unvested restricted stock units, 48,774 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 23,937 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 5,699 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 8,684 of which were granted on March 8, 2024 and shall vest through March 8, 2027, and 76 additional shares acquired under the Issuer's Amended and Restated 2015 Employee Stock Purchase Plan.
NUVASIVE INC
Report date February 01, 2018 · Filed February 05, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,943 |
Last balance in matching sequence
After 2018-02-01 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2018-02-01 · Exercise / conversion · Acquired 931 · Balance 8,323 F1: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Company equity awards. Row 2 · 2018-02-01 · Tax withholding · Disposed 380 · Balance 7,943 F2: Shares withheld by the Issuer to satisfy tax withholding obligations. F1: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Company equity awards. |
| RSUsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 931 |
Reported balance
After 2018-02-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-02-01 · Exercise / conversion · Disposed 931 · Balance 931 F3: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F4: This RSU award was granted to the Reporting Person on February 17, 2015. In accordance with the terms of the RSU award, the award vested as to 932 shares on February 1, 2016, vested as to 931 shares on February 1, 2017 and February 1, 2018 and will vest as to 931 shares on February 1, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Company equity awards.
F2: Shares withheld by the Issuer to satisfy tax withholding obligations.
F3: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.
F4: This RSU award was granted to the Reporting Person on February 17, 2015. In accordance with the terms of the RSU award, the award vested as to 932 shares on February 1, 2016, vested as to 931 shares on February 1, 2017 and February 1, 2018 and will vest as to 931 shares on February 1, 2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 08, 2021 Filed Mar 11, 2021 00:30 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 5,301 | $0.00 | $5.30 |
DisclosureSEC source: 0001093557-21-000058 · edgardoc.xml · nonDerivative · entry 1 Sylvain Jereme M · CIK 0001681267 · SVP, Finance & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,049 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock. F2 · balance_after: Included in this number are 11,837 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 3,654 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 1,608 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 1,274 of which were granted on November 8, 2018 and shall vest through November 8, 2021. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 23:02 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 600 | $404.00 | $242,400.00 |
DisclosureSEC source: 0001093557-21-000034 · edgardoc.xml · nonDerivative · entry 1 Sylvain Jereme M · CIK 0001681267 · SVP, Finance & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,700 F1 · shares: On May 26, 2020, Mr. Sylvain adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sylvain. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 9,169 unvested restricted stock units, 5,483 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 2,412 of which were granted on March 8, 2019 and shall vest through March 8, 2022 and 1,274 of which were granted on November 8, 2018 and shall vest through November 8, 2021. Read SEC document |
| November 24, 2020 Filed Nov 25, 2020 21:50 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 600 | $320.37 | $192,222.00 |
DisclosureSEC source: 0001093557-20-000319 · edgardoc.xml · nonDerivative · entry 1 Sylvain Jereme M · CIK 0001681267 · SVP, Finance & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,300 F1 · shares: On May 26, 2020, Mr. Sylvain adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sylvain. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 9,169 unvested restricted stock units, 5,483 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 2,412 of which were granted on March 8, 2019 and shall vest through March 8, 2022 and 1,274 of which were granted on November 8, 2018 and shall vest through November 8, 2021. Read SEC document |
| November 10, 2020 Filed Nov 12, 2020 22:39 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 632 | $336.22 | $212,491.48 |
DisclosureSEC source: 0001093557-20-000304 · edgardoc.xml · nonDerivative · entry 1 Sylvain Jereme M · CIK 0001681267 · SVP, Finance & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,900 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $336.2100 to $336.8834. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 9,169 unvested restricted stock units, 5,483 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 2,412 of which were granted on March 8, 2019 and shall vest through March 8, 2022 and 1,274 of which were granted on November 8, 2018 and shall vest through November 8, 2021. Read SEC document |
| September 09, 2020 Filed Sep 11, 2020 22:59 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 289 | $398.30 | $115,109.28 |
DisclosureSEC source: 0001093557-20-000257 · edgardoc.xml · nonDerivative · entry 1 Sylvain Jereme M · CIK 0001681267 · SVP, Finance & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,532 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 10,443 unvested restricted stock units, 5,483 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 2,412 of which were granted on March 8, 2019 and shall vest through March 8, 2022 and 2,548 of which were granted on November 8, 2018 and shall vest through November 8, 2021. Read SEC document |
| August 24, 2020 Filed Aug 26, 2020 23:04 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 600 | $427.41 | $256,446.00 |
DisclosureSEC source: 0001093557-20-000235 · edgardoc.xml · nonDerivative · entry 1 Sylvain Jereme M · CIK 0001681267 · SVP, Finance & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,817 F1 · shares: On May 26, 2020, Mr. Sylvain adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sylvain. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 11,247 unvested restricted stock units, 5,483 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 3,216 of which were granted on March 8, 2019 and shall vest through March 8, 2022 and 2,548 of which were granted on November 8, 2018 and shall vest through November 8, 2021. Read SEC document |
| March 11, 2020 Filed Mar 14, 2020 01:17 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 589 | $265.43 | $156,335.91 |
DisclosureSEC source: 0001093557-20-000096 · edgardoc.xml · nonDerivative · entry 2 Sylvain Jereme M · CIK 0001681267 · SVP, Finance & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,417 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 11,247 unvested restricted stock units, 5,483 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 3,216 of which were granted on March 8, 2019 and shall vest through March 8, 2022 and 2,548 of which were granted on November 8, 2018 and shall vest through November 8, 2021. Read SEC document |
| March 11, 2020 Filed Mar 14, 2020 01:17 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 24 | $250.16 | $6,003.92 |
DisclosureSEC source: 0001093557-20-000096 · edgardoc.xml · nonDerivative · entry 1 Sylvain Jereme M · CIK 0001681267 · SVP, Finance & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,006 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 11,247 unvested restricted stock units, 5,483 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 3,216 of which were granted on March 8, 2019 and shall vest through March 8, 2022 and 2,548 of which were granted on November 8, 2018 and shall vest through November 8, 2021. Read SEC document |
| March 08, 2020 Filed Mar 11, 2020 00:23 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 5,483 | $0.00 | $5.48 |
DisclosureSEC source: 0001093557-20-000079 · edgardoc.xml · nonDerivative · entry 1 Sylvain Jereme M · CIK 0001681267 · SVP, Finance & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,030 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock. F2 · balance_after: Included in this number are 11,247 unvested restricted stock units, 5,483 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 3,216 of which were granted on March 8, 2019 and shall vest through March 8, 2022 and 2,548 of which were granted on November 8, 2018 and shall vest through November 8, 2021. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 17:59 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionRSUs · Derivative | 931 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-007632 · doc4.xml · derivative · entry 3 Sylvain Jereme M · CIK 0001681267 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 931 Underlying: Common Stock · 931 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F4 · derivative.exercise_date: This RSU award was granted to the Reporting Person on February 17, 2015. In accordance with the terms of the RSU award, the award vested as to 932 shares on February 1, 2016, vested as to 931 shares on February 1, 2017 and February 1, 2018 and will vest as to 931 shares on February 1, 2019. F4 · derivative.expiration_date: This RSU award was granted to the Reporting Person on February 17, 2015. In accordance with the terms of the RSU award, the award vested as to 932 shares on February 1, 2016, vested as to 931 shares on February 1, 2017 and February 1, 2018 and will vest as to 931 shares on February 1, 2019. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 17:59 UTC | NUVASIVE INC NUVA · Entity 110002 | Tax withholdingCommon Stock | 380 | $48.50 | $18,430.00 |
DisclosureSEC source: 0001209191-18-007632 · doc4.xml · nonDerivative · entry 2 Sylvain Jereme M · CIK 0001681267 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,943 F2 · shares: Shares withheld by the Issuer to satisfy tax withholding obligations. F1 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Company equity awards. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 17:59 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionCommon Stock | 931 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-007632 · doc4.xml · nonDerivative · entry 1 Sylvain Jereme M · CIK 0001681267 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,323 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Company equity awards. Read SEC document |
| July 01, 2017 Filed Jul 5, 2017 17:53 UTC | NUVASIVE INC NUVA · Entity 110002 | Disposition to issuerRSUs · Derivative | 2,091 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-043465 · doc4.xml · derivative · entry 3 Sylvain Jereme M · CIK 0001681267 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,091 Underlying: Common Stock · 2,091 shares Expires not disclosed F3 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F4 · derivative.exercise_date: This RSU award was granted to the Reporting Person on July 1, 2014. In accordance with the terms of the RSU award, the award vested as to 2,091 shares on each of July 1, 2015, July 1, 2016 and July 1, 2017 and will vest as to 2,091 shares on July 1, 2018. F4 · derivative.expiration_date: This RSU award was granted to the Reporting Person on July 1, 2014. In accordance with the terms of the RSU award, the award vested as to 2,091 shares on each of July 1, 2015, July 1, 2016 and July 1, 2017 and will vest as to 2,091 shares on July 1, 2018. Read SEC document |
| July 01, 2017 Filed Jul 5, 2017 17:53 UTC | NUVASIVE INC NUVA · Entity 110002 | Tax withholdingCommon Stock | 785 | $76.92 | $60,382.20 |
DisclosureSEC source: 0001209191-17-043465 · doc4.xml · nonDerivative · entry 2 Sylvain Jereme M · CIK 0001681267 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,392 F2 · shares: Shares withheld by the Issuer to satisfy tax withholding obligations. F1 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Company equity awards. Amount includes 429 shares acquired under the Issuer's employee stock purchase plan in April 2017. Read SEC document |
| July 01, 2017 Filed Jul 5, 2017 17:53 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionCommon Stock | 2,091 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-043465 · doc4.xml · nonDerivative · entry 1 Sylvain Jereme M · CIK 0001681267 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,177 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Company equity awards. Amount includes 429 shares acquired under the Issuer's employee stock purchase plan in April 2017. Read SEC document |
| February 08, 2017 Filed Feb 10, 2017 17:57 UTC | NUVASIVE INC NUVA · Entity 110002 | GrantPRSUs · Derivative | 3,951 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-009694 · doc4.xml · derivative · entry 1 Sylvain Jereme M · CIK 0001681267 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,951 Underlying: Common Stock · 3,951 shares Expires not disclosed F1 · security: Each Performance Restricted Stock Unit ("PRSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: This PRSU award was granted to the Reporting Person on August 1, 2016. On February 8, 2017, the Compensation Committee of the Issuer's Board of Directors certified that the PRSU award's performance condition had been satisfied. In accordance with the terms of the PRSU award, the award will vest in full on August 1, 2019. As the PRSU award did not constitute a derivative security, it was not required to be reported and was not reported on a Form 4 at the time of grant. F2 · derivative.expiration_date: This PRSU award was granted to the Reporting Person on August 1, 2016. On February 8, 2017, the Compensation Committee of the Issuer's Board of Directors certified that the PRSU award's performance condition had been satisfied. In accordance with the terms of the PRSU award, the award will vest in full on August 1, 2019. As the PRSU award did not constitute a derivative security, it was not required to be reported and was not reported on a Form 4 at the time of grant. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 18:03 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionRSUs · Derivative | 931 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-007796 · doc4.xml · derivative · entry 3 Sylvain Jereme M · CIK 0001681267 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,862 Underlying: Common Stock · 931 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F4 · derivative.exercise_date: This RSU award was granted to the Reporting Person on February 17, 2015. In accordance with the terms of the RSU award, the award vested as to 932 shares on February 1, 2016, vested as to 931 shares on February 1, 2017, and will vest as to 931 shares on each of February 1, 2018 and February 1, 2019. F4 · derivative.expiration_date: This RSU award was granted to the Reporting Person on February 17, 2015. In accordance with the terms of the RSU award, the award vested as to 932 shares on February 1, 2016, vested as to 931 shares on February 1, 2017, and will vest as to 931 shares on each of February 1, 2018 and February 1, 2019. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 18:03 UTC | NUVASIVE INC NUVA · Entity 110002 | Tax withholdingCommon Stock | 407 | $70.76 | $28,799.32 |
DisclosureSEC source: 0001209191-17-007796 · doc4.xml · nonDerivative · entry 2 Sylvain Jereme M · CIK 0001681267 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,657 F2 · shares: Shares withheld by the Issuer to satisfy tax withholding obligations. F1 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Company equity awards. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 18:03 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionCommon Stock | 931 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-007796 · doc4.xml · nonDerivative · entry 1 Sylvain Jereme M · CIK 0001681267 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,064 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Company equity awards. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.